For decades, the treatment paradigm for operable brain metastases has remained remarkably consistent. Patients undergo surgical resection, recover for several weeks, and then receive postoperative stereotactic radiosurgery (SRS) to eliminate microscopic residual disease.
This sequence has become the standard of care because randomized trials demonstrated that postoperative SRS substantially reduces local recurrence while avoiding the neurocognitive toxicity associated with whole-brain radiotherapy.
The Phase III ROADS trial(Weinberg et al., 2026), presented as a late-breaking abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, challenges this approach: must radiation wait until after surgical recovery?
GammaTile differs basically from kilovoltage intraoperative radiotherapy by delivering radiation continuously through permanently implanted cesium-131 sources rather than a single intraoperative exposure, thereby combining the advantages of immediate treatment with sustained low-dose-rate irradiation.
The evidence shows that the timing of radiation delivery may be as important as advances in radiation technology itself.
The Clinical Impact Extends Beyond Local Recurrence
The multicenter ROADS trial randomized 230 patients with newly diagnosed operable brain metastases across 32 centers to receive either GammaTile tile-based radiation therapy (TBRT) at the time of surgery or standard postoperative stereotactic radiation therapy.
GammaTile reduced the 12-month surgical bed recurrence rate from 11.9% with contemporary postoperative stereotactic radiotherapy to only 1.0%, representing one of the lowest local recurrence rates reported in a prospective trial of resected brain metastases.
More importantly, the benefit reached beyond local control. Patients receiving GammaTile experienced a greater than 50% reduction in the risk of surgical bed recurrence or death (hazard ratio 0.48), while estimated two-year overall survival improved from 35.7% to 61.7%.
Equally important, these gains were achieved without increased toxicity, radiation necrosis, deterioration in quality of life, or functional decline, dealing with one of the principal concerns surrounding intracavitary brachytherapy.
Why Might Immediate Radiation Matter?
Conventional postoperative SRS is generally delivered several weeks after surgery. During this interval, residual microscopic tumor cells are exposed to a postoperative microenvironment characterized by wound healing, inflammatory signaling, angiogenesis, and tissue remodeling.
Whether these processes contribute to postoperative tumor repopulation is still an area of active investigation. GammaTile eliminates this interval.
Cesium-131 seeds begin emitting radiation immediately after implantation and deliver most of the prescribed dose within the first month owing to the isotope and short 9.7-day half-life.
Unlike single- or hypofractionated SRS, this approach delivers continuous low-dose-rate irradiation of the surgical cavity during the immediate postoperative period, when the burden of residual microscopic disease is lowest.
Several mechanisms may contribute to the observed clinical benefit:
- Immediate treatment of microscopic residual disease before postoperative repopulation.
- Continuous low-dose-rate irradiation extends treatment beyond the operating room, maintaining radiation exposure during the critical postoperative period when residual
microscopic disease may begin to proliferate, thereby exposing residual tumor cells as they re-enter the cell cycle over time. - Placement of cesium-131 sources along the resection cavity provides homogeneous coverage of the cavity surface while exploiting the rapid dose fall-off of low-energy photons to spare the adjacent normal brain. Although the relative contribution of each mechanism remains unknown, the trial suggests that the timing and dose rate of radiation may represent previously underappreciated determinants of postoperative tumor control.
Completing Local Therapy in a Single Procedure
Patients treated with GammaTile completed definitive local therapy in a median of one day, compared with approximately 30 days for patients receiving postoperative stereotactic radiation.
Integrating surgery and radiation into a single procedure may reduce delays in initiating systemic therapy, eliminate the risk of patients not receiving postoperative radiation, lessen the travel burden, and simplify multidisciplinary care.
This difference goes beyond convenience. As systemic therapies continue to improve survival for patients with metastatic cancer, optimizing local treatment pathways becomes increasingly important.
What Questions Remain?
Despite the considerable improvements in local control and survival, several important questions remain. The trial demonstrated similar rates of leptomeningeal disease, distant brain failure, radiation necrosis, adverse events, and quality of life between treatment groups.
This evidence suggests that while GammaTile dramatically improves control of the surgical cavity, meningeal dissemination may be driven by biological mechanisms distinct from those underlying local recurrence within the cavity. Another important unanswered question concerns patterns of local failure.
Unlike conventional postoperative SRS studies, which frequently report patterns of local failure, the initial ROADS presentation focused on overall surgical bed recurrence rather than the anatomical distribution of recurrence.
Although the exceptionally low surgical bed recurrence rate suggests excellent control of residual microscopic disease, future analyses should distinguish parenchymal cavity recurrence, pachymeningeal (dural) recurrence, and nodular leptomeningeal recurrence.
Immediate intracavitary irradiation may preferentially sterilize microscopic tumor deposits along the cavity–dural interface, but whether this translates into lower rates of pachymeningeal failure has not yet been reported.
A longer follow-up will also clarify the durability of the survival benefit and identify which patient subgroups derive the greatest advantage from immediate intracavitary brachytherapy. Finally, integration with contemporary systemic therapies—including targeted agents and immunotherapy—will be an important area for future investigation.
Written by Ahmed Galal, MD
Discover more articles like this on OncoDaily.